Assets

Hu-VHH Antibody Assets

The Single VHH domain (~12-15 kDa) allows for better penetration of solid tumors and the blood-brain barrier, representing promising diagnostic and therapeutic approaches.

  • 200+
    VHH Projects
  • ～150
    Antibody Asset Partnerships
related resource

on this page

  • Exploring New Opportunities of Biocytogen's Hu-VHH in Multi-Specific Antibodies, ADCs, and Cell Therapies
  • Biocytogen's RenNano Mice: A Fully Human Heavy Chain-Only Platform for VHH Discovery
  • RenNano Platform Related Antibody Library

Webinars

View All

    Posters

    View All
      Exploring New Opportunities of Biocytogen's Hu-VHH in Multi-Specific Antibodies, ADCs, and Cell Therapies

      The single VHH domain (~12-15 kDa), which allows for better penetration of solid tumors and the blood-brain barrier, represents a promising diagnostic and therapeutic approach.

      Biocytogen's RenNano Mice: A Fully Human Heavy Chain-Only Platform for VHH Discovery

      RenNano mice were developed via genetic modification of the antibody constant region in RenMab mice. Following immunization, RenNano mice produce fully human heavy-chain-only antibodies (HCAbs) that can bind to antigens without a light chain. RenNano-derived HCAbs possess diverse CDR3 sequences and can recognize a variety of epitopes with excellent specificity and affinity. HCAbs derived from RenNano mice demonstrate robust biological function both in vitro and in vivo, making them suitable for various drug modalities, including bispecific antibodies, multispecific antibodies, ADC and cell therapies. Using RenNano mice, Biocytogen initiated the "Nano 100 Project" in February 2023 to discover fully human therapeutic VHHs against over 100 different targets.

      RenNano Platform Related Antibody Library
      Target Dev Stage Species cross-reactivity Internalization Assay Affinity
      CD71 Leads Selection √ √ √
      CD98 Leads Selection √ √ √
      MUC16 Leads Selection √ √ √
      PSMA Leads Selection √ √ √
      MET Leads Selection √ √ √
      4-1BB Leads Selection √ NA √
      VEGFA Leads Selection √ NA √
      ALB Leads Selection √ NA √
      RSV Leads Selection NA NA √
      DLL3 Leads Selection √ √ √
      CD28 Leads Selection √ NA √
      CD3e Leads Selection √ NA √
      EGFR Leads Selection √ √ √
      PD-L1 Hits Selection √ NA √
      TNFR2 Hits Selection √ NA √
      CD38 Hits Selection √ NA √
      GPRC5D Hits Selection √ √ √
      HER3 Hits Selection √ √ √
      GUCY2C Hits Selection √ √ √
      IL6ST Hits Selection √ NA √
      IL6R Hits Selection √ NA √
      ADAM9 Hits Selection √ NA √
      FAP Hits Selection √ √ √
      PTK7 Hits Selection √ √ √
      TPBG Hits Selection √ In progress In progress
      IL3RA Hits Selection √ NA √
      MSLN Hits Selection √ √ √
      TSLP Hits Selection √ NA In progress
      OX40 Hits Selection √ NA √
      TROP2 Hits Selection √ √ √
      Nectin-4 Hits Selection √ √ √
      ROR1 Hits Selection √ √ √
      CD22 Hits Selection √ NA √
      FOLR1 Hits Selection √ √ √
      IL13RA2 Hits Selection √ NA √
      Case Study 1: Selective Assets for TFR1-TOP HCAbs

      CD71, also known as TFR1 (Transferrin receptor), a single transmembrane, mainly transports Fe ions into cells by binding to Transferrin TF (Transferrin). Anti-TFR1 antibody are widely used as BBB shuttle.

      TFR1-TOP Antibody demonstrated better BBB penetrance efficacy and advantage in in vivo.

      • Better BBB penetrance performance than benchmark antibody.
      • Monovalent perform much better BBB penetrance than Bivalent form.
      • Flexibly suited for non-conjugation shuttling (e.g. fusions or bsAbs) or conjugated payload shuttling (e.g. AOC or small molecules).
      Better BBB penetrance than Benchmark
      Monovalent vs. Bivalent